In October 2003 Shenzhen SiBiono Ge...

In October 2003 Shenzhen SiBiono GeneTech made history at becoming the first company approved to market a gene therapy medication. China's State aliment and Drug Administration (SFDA) approved Gendicine for treatment of head and neck squamous small room carcinoma (HNSCC). SiBiono believes that continued clinical trials will submit to the test [i]or[/i] proof Gendicine to be effective as a wide-spectrum anticancer agent.

In March, BioPharm International interviewed Dr Zhaohui Peng SiBiono's go to the bottom chairman, and CEO, to learn more about the science behind gene therapy, the clinical experience with Gendicine, and